Palo Alto Investors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Palo Alto Investors’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-167,302	Closed	-$555K	–	42
2016 Q3	$555K	Hold	167,302	–	–	0.03%	39
2016 Q2	$719K	Hold	167,302	–	–	0.05%	42
2016 Q1	$941K	Hold	167,302	–	–	0.07%	39
2015 Q4	$2.88M	Sell	167,302 -25,830	-13%	-$616K	0.16%	34
2015 Q3	$4.08M	Hold	193,132	–	–	0.2%	35
2015 Q2	$9.56M	Hold	193,132	–	–	0.43%	31
2015 Q1	$15.1M	Hold	193,132	–	–	0.75%	31
2014 Q4	$11.7M	Hold	193,132	–	–	0.69%	31
2014 Q3	$8.23M	Hold	193,132	–	–	0.61%	33
2014 Q2	$11.9M	Buy	193,132 +26,230	+16%	+$1.53M	0.89%	30
2014 Q1	$10.8M	Buy	+166,902	New	+$11.3M	0.9%	25

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Palo Alto Investors's OREX Position: Q4 2016 in Review

Palo Alto Investors sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2016, closing a stake of 167,302 shares — an estimated $555K sold.

Palo Alto Investors first reported a position in OREX in Q1 2014 and held it in 11 quarters. The position peaked at $15.1M in Q1 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

Palo Alto Investors reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Palo Alto Investors sold 167,302 Orexigen Therapeutics, Inc. shares in Q4 2016, an estimated $555K.
Palo Alto Investors first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 11 quarters.
Palo Alto Investors's Orexigen Therapeutics, Inc. position peaked at $15.1M in Q1 2015.
53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on Palo Alto Investors's 13F filing for Q4 2016, filed 15 Feb 2017.